Comparative Pharmacology
Head-to-head clinical analysis: HEXADROL versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXADROL versus MAGNACORT.
HEXADROL vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category C
Category C
Corticosteroid
Corticosteroid